vs
Side-by-side financial comparison of Bitcoin Depot Inc. (BTM) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $162.5M, roughly 1.0× Bitcoin Depot Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 20.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -4.9%).
Bitcoin Depot Inc. is one of the largest cryptocurrency ATM operators across North America. It provides retail consumers with accessible in-person kiosks to buy and sell Bitcoin and other leading digital assets, alongside online crypto purchase services via bank transfer. Its self-service kiosks are located in high-traffic retail spaces including grocery stores, gas stations and convenience stores.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BTM vs ESPR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $162.5M | $168.4M |
| Net Profit | $5.5M | — |
| Gross Margin | — | — |
| Operating Margin | 7.3% | 50.6% |
| Net Margin | 3.4% | — |
| Revenue YoY | 20.1% | 143.7% |
| Net Profit YoY | 690.4% | — |
| EPS (diluted) | $0.08 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $168.4M | ||
| Q3 25 | $162.5M | $87.3M | ||
| Q2 25 | $172.1M | $82.4M | ||
| Q1 25 | $164.2M | $65.0M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | $135.3M | $51.6M | ||
| Q2 24 | $163.1M | $73.8M | ||
| Q1 24 | $138.5M | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | $5.5M | $-31.3M | ||
| Q2 25 | $6.1M | $-12.7M | ||
| Q1 25 | $4.2M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-939.0K | $-29.5M | ||
| Q2 24 | $-2.6M | $-61.9M | ||
| Q1 24 | $-1.5M | $61.0M |
| Q4 25 | — | 50.6% | ||
| Q3 25 | 7.3% | -11.4% | ||
| Q2 25 | 9.2% | 8.6% | ||
| Q1 25 | 10.8% | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | 4.1% | -31.0% | ||
| Q2 24 | 4.7% | 3.5% | ||
| Q1 24 | 0.5% | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | 3.4% | -35.9% | ||
| Q2 25 | 3.5% | -15.4% | ||
| Q1 25 | 2.6% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.7% | -57.2% | ||
| Q2 24 | -1.6% | -83.9% | ||
| Q1 24 | -1.1% | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | $0.08 | $-0.16 | ||
| Q2 25 | $0.16 | $-0.06 | ||
| Q1 25 | $0.20 | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | $-0.05 | $-0.15 | ||
| Q2 24 | $-0.13 | $-0.33 | ||
| Q1 24 | $-0.25 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $59.3M | $167.9M |
| Total DebtLower is stronger | $67.5M | — |
| Stockholders' EquityBook value | $21.0M | $-302.0M |
| Total Assets | $125.3M | $465.9M |
| Debt / EquityLower = less leverage | 3.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | $59.3M | $92.4M | ||
| Q2 25 | $48.0M | $86.1M | ||
| Q1 25 | $35.0M | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | $32.2M | $144.7M | ||
| Q2 24 | $43.9M | $189.3M | ||
| Q1 24 | $42.2M | $226.6M |
| Q4 25 | — | — | ||
| Q3 25 | $67.5M | — | ||
| Q2 25 | $66.5M | — | ||
| Q1 25 | $56.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $44.5M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $37.6M | — |
| Q4 25 | — | $-302.0M | ||
| Q3 25 | $21.0M | $-451.4M | ||
| Q2 25 | $4.7M | $-433.5M | ||
| Q1 25 | $-4.6M | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | $-7.9M | $-370.2M | ||
| Q2 24 | $4.4M | $-344.2M | ||
| Q1 24 | $5.0M | $-294.3M |
| Q4 25 | — | $465.9M | ||
| Q3 25 | $125.3M | $364.0M | ||
| Q2 25 | $109.1M | $347.1M | ||
| Q1 25 | $89.7M | $324.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | $87.4M | $314.1M | ||
| Q2 24 | $97.5M | $352.3M | ||
| Q1 24 | $90.1M | $373.1M |
| Q4 25 | — | — | ||
| Q3 25 | 3.21× | — | ||
| Q2 25 | 14.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 9.27× | — | ||
| Q1 24 | 7.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $45.2M |
| Free Cash FlowOCF − Capex | $2.5M | — |
| FCF MarginFCF / Revenue | 1.6% | — |
| Capex IntensityCapex / Revenue | 2.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.2M | ||
| Q3 25 | $6.6M | $-4.3M | ||
| Q2 25 | $10.2M | $-31.4M | ||
| Q1 25 | $16.3M | $-22.6M | ||
| Q4 24 | — | $-35.0M | ||
| Q3 24 | $5.8M | $-35.3M | ||
| Q2 24 | $10.1M | $-7.2M | ||
| Q1 24 | $1.3M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $15.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.0M | $-35.5M | ||
| Q2 24 | $7.6M | $-7.3M | ||
| Q1 24 | $789.0K | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 5.7% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.8% | -68.7% | ||
| Q2 24 | 4.7% | -9.9% | ||
| Q1 24 | 0.6% | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 2.5% | 0.0% | ||
| Q2 25 | 0.2% | 0.0% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 5.0% | 0.3% | ||
| Q2 24 | 1.5% | 0.1% | ||
| Q1 24 | 0.4% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.67× | — | ||
| Q1 25 | 3.88× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTM
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
